ZA200610259B - Acyclovir formulations - Google Patents
Acyclovir formulations Download PDFInfo
- Publication number
- ZA200610259B ZA200610259B ZA200610259A ZA200610259A ZA200610259B ZA 200610259 B ZA200610259 B ZA 200610259B ZA 200610259 A ZA200610259 A ZA 200610259A ZA 200610259 A ZA200610259 A ZA 200610259A ZA 200610259 B ZA200610259 B ZA 200610259B
- Authority
- ZA
- South Africa
- Prior art keywords
- acyclovir
- alkyl
- alkenyl
- pharmaceutical composition
- delivery agent
- Prior art date
Links
- 229960004150 aciclovir Drugs 0.000 title claims description 131
- 239000000203 mixture Substances 0.000 title claims description 67
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title claims description 24
- 238000009472 formulation Methods 0.000 title claims description 20
- 229940124447 delivery agent Drugs 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 31
- 125000003342 alkenyl group Chemical group 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 241000700605 Viruses Species 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 14
- 241000701022 Cytomegalovirus Species 0.000 claims description 13
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 208000009889 Herpes Simplex Diseases 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 229960002446 octanoic acid Drugs 0.000 claims description 9
- 229940107931 zovirax Drugs 0.000 claims description 9
- -1 C.-C Chemical group 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 8
- 125000000732 arylene group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 5
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229960004063 propylene glycol Drugs 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 102100037328 Chitotriosidase-1 Human genes 0.000 claims 1
- 101000879661 Homo sapiens Chitotriosidase-1 Proteins 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- CEYGNZMCCVVXQW-UHFFFAOYSA-N phosphoric acid;propane-1,2-diol Chemical compound CC(O)CO.OP(O)(O)=O CEYGNZMCCVVXQW-UHFFFAOYSA-N 0.000 claims 1
- XUHVCHNJCBBXMP-UHFFFAOYSA-M sodium;10-[(2-hydroxybenzoyl)amino]decanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCCCC([O-])=O XUHVCHNJCBBXMP-UHFFFAOYSA-M 0.000 claims 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 119
- 235000002639 sodium chloride Nutrition 0.000 description 41
- 238000012384 transportation and delivery Methods 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 208000007514 Herpes zoster Diseases 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 6
- 229940093257 valacyclovir Drugs 0.000 description 6
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 208000001688 Herpes Genitalis Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000004946 genital herpes Diseases 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- NJLNVKWPWHGEIM-UHFFFAOYSA-N 8-(4-hydroxyphenoxy)octanoic acid Chemical compound OC(=O)CCCCCCCOC1=CC=C(O)C=C1 NJLNVKWPWHGEIM-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 201000006082 Chickenpox Diseases 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 3
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010046980 Varicella Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 229960002555 zidovudine Drugs 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 206010048461 Genital infection Diseases 0.000 description 2
- 208000005794 Hairy Leukoplakia Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011867 re-evaluation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 208000010531 varicella zoster infection Diseases 0.000 description 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
- KMTZFYVMJZEGTJ-UHFFFAOYSA-N 2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethyl pentanoate Chemical compound N1=C(N)NC(=O)C2=C1N(COCCOC(=O)CCCC)C=N2 KMTZFYVMJZEGTJ-UHFFFAOYSA-N 0.000 description 1
- QZQNMMLYACBCMJ-UHFFFAOYSA-N 2-[2-hydroxyethyl(octyl)amino]ethanol Chemical compound CCCCCCCCN(CCO)CCO QZQNMMLYACBCMJ-UHFFFAOYSA-N 0.000 description 1
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- DPYOCWVIULRBQV-UHFFFAOYSA-N 6-(2-cyanophenoxy)hexanoic acid Chemical compound OC(=O)CCCCCOC1=CC=CC=C1C#N DPYOCWVIULRBQV-UHFFFAOYSA-N 0.000 description 1
- CMXWSGRDJPSEQH-UHFFFAOYSA-N 8-[(2,6-dihydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=C(O)C=CC=C1O CMXWSGRDJPSEQH-UHFFFAOYSA-N 0.000 description 1
- QSEXGCYGWQFHIF-UHFFFAOYSA-N 8-[(2-hydroxy-4-methoxybenzoyl)amino]octanoic acid Chemical compound COC1=CC=C(C(=O)NCCCCCCCC(O)=O)C(O)=C1 QSEXGCYGWQFHIF-UHFFFAOYSA-N 0.000 description 1
- PGPTYXPNOQRZBZ-UHFFFAOYSA-N 8-[(2-hydroxy-5-iodobenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(I)=CC=C1O PGPTYXPNOQRZBZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010073931 Genital herpes simplex Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000005864 Sulphur Chemical group 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940008235 acyclovir sodium Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical group CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000004565 water dispersible tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57300304P | 2004-05-19 | 2004-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200610259B true ZA200610259B (en) | 2007-12-27 |
Family
ID=35428245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200610259A ZA200610259B (en) | 2004-05-19 | 2006-12-08 | Acyclovir formulations |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20080132527A1 (fr) |
| EP (1) | EP1750718B1 (fr) |
| JP (1) | JP5122954B2 (fr) |
| KR (1) | KR101342065B1 (fr) |
| CN (1) | CN1968699B (fr) |
| AU (1) | AU2005244985B2 (fr) |
| BR (1) | BRPI0510820A (fr) |
| CA (1) | CA2566741C (fr) |
| HK (1) | HK1097751A1 (fr) |
| IL (1) | IL179177A (fr) |
| MX (1) | MXPA06013295A (fr) |
| NO (1) | NO20065791L (fr) |
| NZ (1) | NZ551455A (fr) |
| RU (1) | RU2406504C2 (fr) |
| WO (1) | WO2005112937A1 (fr) |
| ZA (1) | ZA200610259B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007133944A2 (fr) * | 2006-05-09 | 2007-11-22 | Emisphere Technologies, Inc. | Administration topique d'acyclovir |
| CA2661018C (fr) * | 2006-08-18 | 2015-11-24 | Emisphere Technologies, Inc. | Synthese d'ethers propylphenoxy et leur utilisation comme agents d'administration |
| USRE48164E1 (en) | 2006-08-31 | 2020-08-18 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
| WO2008070543A1 (fr) * | 2006-12-01 | 2008-06-12 | Emisphere Technologies Inc. | Formulations améliorées à base d'aciclovir |
| US20090124639A1 (en) * | 2007-11-06 | 2009-05-14 | Emisphere Technologies Inc. | valacyclovir formulations |
| JP5985985B2 (ja) * | 2009-08-03 | 2016-09-06 | エミスフィアー テクノロジーズ インコーポレイテッドＥｍｉｓｐｈｅｒｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｉｎｃ． | 胃腸への影響が減少した即効型ナプロキセン組成物 |
| US20140271772A1 (en) * | 2013-03-15 | 2014-09-18 | Barry J. Margulies | Biodegradable subcutaneous implants and methods of making |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4199574A (en) * | 1974-09-02 | 1980-04-22 | Burroughs Wellcome Co. | Methods and compositions for treating viral infections and guanine acyclic nucleosides |
| GB1523865A (en) | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
| GB8815241D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Antiviral combinations & compounds therefor |
| US5693338A (en) | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
| US6221367B1 (en) | 1992-06-15 | 2001-04-24 | Emisphere Technologies, Inc. | Active agent transport systems |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5541155A (en) | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
| US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| US5443841A (en) | 1992-06-15 | 1995-08-22 | Emisphere Technologies, Inc. | Proteinoid microspheres and methods for preparation and use thereof |
| US5578323A (en) | 1992-06-15 | 1996-11-26 | Emisphere Technologies, Inc. | Proteinoid carriers and methods for preparation and use thereof |
| US5451410A (en) | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
| US6099856A (en) | 1992-06-15 | 2000-08-08 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5447728A (en) | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
| US5629016A (en) | 1991-01-30 | 1997-05-13 | Glaxo Wellcome Inc. | Water-dispersible tablets |
| US5384333A (en) * | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
| US6916489B2 (en) | 1992-06-15 | 2005-07-12 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5811127A (en) | 1992-06-15 | 1998-09-22 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
| US5401516A (en) | 1992-12-21 | 1995-03-28 | Emisphere Technologies, Inc. | Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof |
| IL104283A (en) * | 1992-12-30 | 1996-12-05 | Agis Ind 1983 Ltd | Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate |
| US20040062773A1 (en) | 1993-04-22 | 2004-04-01 | Emisphere Technologies Inc. | Compositions for the delivery of antigens |
| US5958457A (en) | 1993-04-22 | 1999-09-28 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| ATE298561T1 (de) | 1993-04-22 | 2005-07-15 | Emisphere Tech Inc | Orale dareichungsform |
| US6610329B2 (en) | 1993-04-22 | 2003-08-26 | Emisphere Technologies Inc. | Compositions for the delivery of antigens |
| US20010003001A1 (en) | 1993-04-22 | 2001-06-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5965121A (en) | 1995-03-31 | 1999-10-12 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5989539A (en) | 1995-03-31 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US6090958A (en) | 1995-03-31 | 2000-07-18 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CN1151836C (zh) | 1995-03-31 | 2004-06-02 | 艾米斯菲尔技术有限公司 | 用作传送活性剂的化合物和组合物 |
| US5820881A (en) | 1995-04-28 | 1998-10-13 | Emisphere Technologies, Inc. | Microspheres of diamide-dicarboxylic acids |
| US5883103A (en) * | 1995-06-07 | 1999-03-16 | Shire Laboratories Inc. | Oral acyclovir delivery |
| US5824345A (en) | 1995-06-07 | 1998-10-20 | Emisphere Technologies, Inc. | Fragrances and flavorants |
| US5667806A (en) | 1995-06-07 | 1997-09-16 | Emisphere Technologies, Inc. | Spray drying method and apparatus |
| US6051258A (en) | 1995-06-07 | 2000-04-18 | Emisphere Technologies, Inc. | Proteinoid emulsions and methods for preparation and use thereof |
| US5750147A (en) | 1995-06-07 | 1998-05-12 | Emisphere Technologies, Inc. | Method of solubilizing and encapsulating itraconazole |
| US6084112A (en) | 1995-09-11 | 2000-07-04 | Emisphere Technologies, Inc. | Method for preparing ω-aminoalkanoic acid derivatives from cycloalkanones |
| AU2420997A (en) | 1996-02-29 | 1997-09-16 | Emisphere Technologies, Inc. | Oligopeptides for drug delivery |
| IL126318A (en) | 1996-03-29 | 2004-09-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents and some novel carrier compounds |
| AU3828597A (en) | 1996-06-14 | 1998-01-07 | Emisphere Technologies, Inc. | Microencapsulated fragrances and method for preparation |
| US5958451A (en) | 1996-09-03 | 1999-09-28 | Yung Shin Pharm Ind. Co., Ltd. | Process for producing porous, controlled-release capsules and encapsulated composition |
| CA2243643A1 (fr) | 1996-11-18 | 1998-05-28 | Susan Haas | Procede et composition pour induire une tolerance orale chez les mammiferes |
| US5776888A (en) | 1997-02-07 | 1998-07-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5939381A (en) | 1997-02-07 | 1999-08-17 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5990166A (en) | 1997-02-07 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6358504B1 (en) | 1997-02-07 | 2002-03-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6060513A (en) | 1997-02-07 | 2000-05-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5876710A (en) | 1997-02-07 | 1999-03-02 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
| ATE383169T1 (de) | 1997-02-07 | 2008-01-15 | Emisphere Tech Inc | Komponente und zusammensetzungen zur verabreichung von wirkstoffen |
| US5804688A (en) | 1997-02-07 | 1998-09-08 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6051561A (en) | 1997-02-07 | 2000-04-18 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
| US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
| US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5863944A (en) | 1997-04-30 | 1999-01-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5962710A (en) | 1997-05-09 | 1999-10-05 | Emisphere Technologies, Inc. | Method of preparing salicyloylamino acids |
| US6440929B1 (en) | 1998-07-27 | 2002-08-27 | Emisphere Technologies, Inc. | Pulmonary delivery of active agents |
| JP4675481B2 (ja) | 1998-07-27 | 2011-04-20 | エミスフェアー・テクノロジーズ・インク | 活性剤の肺性デリバリー |
| BR9912975A (pt) | 1998-08-07 | 2001-09-25 | Emisphere Tech Inc | Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso |
| US6635281B2 (en) * | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
| NZ512581A (en) | 1999-01-08 | 2002-12-20 | Univ Virginia Commonwealth | Polymeric delivery agents comprising a polymer conjugated to a modified amino acid and derivatives thereof |
| WO2000046182A1 (fr) | 1999-02-05 | 2000-08-10 | Emisphere Technologies, Inc. | Procede de preparation de salicylamides alkyles |
| EP1156787B1 (fr) | 1999-02-11 | 2005-11-30 | Emisphere Technologies, Inc. | Composes a base d'oxadiazole et compositions destinees a l'apport d'agents actifs |
| WO2000048589A1 (fr) | 1999-02-22 | 2000-08-24 | Emisphere Holdings, Inc. | Forme posologique orale solide contenant de l'heparine ou un heparinoide combinee a un support |
| JP4637365B2 (ja) | 1999-02-26 | 2011-02-23 | エミスフェアー・テクノロジーズ・インク | 活性剤デリバリーのための化合物及び組成物 |
| CA2369591C (fr) | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Sels disodiques, monohydrate, et solvates d'ethanol |
| AU4218400A (en) | 1999-04-05 | 2000-10-23 | Emisphere Technologies, Inc. | Lyophilized solid dosage forms and methods of making |
| CA2388240C (fr) | 1999-11-05 | 2010-04-20 | Emisphere Technologies, Inc. | Composes d'acide carboxylique phenoxy et compositions utilisees afin de diffuser des agents actifs |
| MXPA02004741A (es) | 1999-11-12 | 2003-12-11 | Emisphere Tech Inc | Formulacion liquida de heparina. |
| EP1237872B1 (fr) | 1999-12-16 | 2008-02-27 | Emisphere Technologies, Inc. | Composes et compositions facilitant l'administration d'agents actifs |
| WO2001051454A1 (fr) | 2000-01-13 | 2001-07-19 | Emisphere Technologies, Inc. | Composes et compositions permettant d"administrer des principes actifs |
| US6693898B1 (en) | 2000-02-01 | 2004-02-17 | Lucent Technologies, Inc. | Call control model for a packet-based intelligent telecommunications network |
| US6384278B1 (en) | 2000-02-04 | 2002-05-07 | Emisphere Technologies, Inc. | Boron-mediated amidation of carboxylic acids |
| JP4799794B2 (ja) | 2000-03-21 | 2011-10-26 | エミスフェアー・テクノロジーズ・インク | ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。 |
| WO2001092206A1 (fr) | 2000-06-02 | 2001-12-06 | Emisphere Technologies, Inc. | Procede de preparation de salicylamides |
| PT1299348E (pt) | 2000-06-29 | 2008-05-12 | Emisphere Tech Inc | Compostos e composições para administração de agentes activos |
| AU2001284985A1 (en) | 2000-08-18 | 2002-03-04 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| EP1326825A2 (fr) | 2000-08-18 | 2003-07-16 | Emisphere Technologies, Inc. | Composes et compositions permettant de distribuer des agents actifs |
| WO2002020466A1 (fr) * | 2000-09-06 | 2002-03-14 | Emisphere Technologies, Inc. | Composes d'acide cyanophenoxycarboxylique et compositions servant a administrer des agents actifs |
| EP1322595B1 (fr) | 2000-09-06 | 2008-05-28 | Emisphere Technologies, Inc. | Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs |
| WO2002070438A2 (fr) | 2001-03-01 | 2002-09-12 | Emisphere Technologies, Inc. | Compositions permettant l'administration de biophosphonates |
| NZ527026A (en) | 2001-03-01 | 2006-01-27 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
| US20030225300A1 (en) | 2001-04-19 | 2003-12-04 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
| WO2002100338A2 (fr) | 2001-06-08 | 2002-12-19 | Emisphere Technologies, Inc. | Compose et composition permettant d'administrer des principes actifs |
| US7411084B2 (en) | 2001-09-26 | 2008-08-12 | Emisphere Technologies, Inc. | Method of preparing phenoxy alkanoic, alkenoic, and alkynoic acids and salts thereof via a dicarboxylate intermediate |
| EP1453816B1 (fr) | 2001-11-13 | 2013-09-18 | Emisphere Technologies, Inc. | Composes phenoxy amine et compositions pour administrer des principes actifs |
| CA2466863A1 (fr) | 2001-11-29 | 2003-06-05 | Emisphere Technologies, Inc. | Compositions pharmaceutiques orales renfermant du cromoglycate sodique et un acide amine acylate |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| AU2003223158B2 (en) | 2002-01-09 | 2008-01-17 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate |
| ATE511868T1 (de) * | 2002-09-12 | 2011-06-15 | Asahi Kasei Kuraray Medical Co | Plasma-reinigungsmembran und plasma- reinigungssystem |
| MXPA05002728A (es) * | 2002-09-13 | 2005-07-25 | Cydex Inc | Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada. |
| JP5452843B2 (ja) | 2003-01-06 | 2014-03-26 | エミスフィアー テクノロジーズ インコーポレイテッド | 夜間の経口インスリン治療 |
| EP1605895A4 (fr) | 2003-03-06 | 2011-08-24 | Emisphere Tech Inc | Insulinotherapies orales et protocole |
| WO2004104018A2 (fr) * | 2003-05-14 | 2004-12-02 | Emisphere Technologies, Inc. | Compostions d'administration de peptide yy de d'agonistes pyy |
| EP1745007A2 (fr) * | 2004-04-16 | 2007-01-24 | Emisphere Technologies, Inc. | 8-(2-hydroxyphenoxy)octyldiethanolamine et ses sels utile dans l'administration d'agents actifs |
-
2005
- 2005-05-19 BR BRPI0510820-9A patent/BRPI0510820A/pt not_active IP Right Cessation
- 2005-05-19 AU AU2005244985A patent/AU2005244985B2/en not_active Ceased
- 2005-05-19 RU RU2006140794/15A patent/RU2406504C2/ru not_active IP Right Cessation
- 2005-05-19 CN CN200580019347XA patent/CN1968699B/zh not_active Expired - Fee Related
- 2005-05-19 JP JP2007527492A patent/JP5122954B2/ja not_active Expired - Fee Related
- 2005-05-19 MX MXPA06013295A patent/MXPA06013295A/es active IP Right Grant
- 2005-05-19 NZ NZ551455A patent/NZ551455A/en not_active IP Right Cessation
- 2005-05-19 US US11/568,826 patent/US20080132527A1/en not_active Abandoned
- 2005-05-19 EP EP05751979.5A patent/EP1750718B1/fr not_active Not-in-force
- 2005-05-19 CA CA2566741A patent/CA2566741C/fr not_active Expired - Fee Related
- 2005-05-19 WO PCT/US2005/017815 patent/WO2005112937A1/fr active Application Filing
-
2006
- 2006-11-09 IL IL179177A patent/IL179177A/en not_active IP Right Cessation
- 2006-12-08 ZA ZA200610259A patent/ZA200610259B/en unknown
- 2006-12-14 NO NO20065791A patent/NO20065791L/no not_active Application Discontinuation
- 2006-12-19 KR KR1020067026797A patent/KR101342065B1/ko not_active IP Right Cessation
-
2007
- 2007-04-18 HK HK07104091A patent/HK1097751A1/xx not_active IP Right Cessation
-
2013
- 2013-03-15 US US13/839,936 patent/US8952017B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL179177A0 (en) | 2007-05-15 |
| EP1750718B1 (fr) | 2014-08-13 |
| JP2007538100A (ja) | 2007-12-27 |
| KR101342065B1 (ko) | 2013-12-19 |
| CN1968699A (zh) | 2007-05-23 |
| WO2005112937A1 (fr) | 2005-12-01 |
| BRPI0510820A (pt) | 2007-11-27 |
| IL179177A (en) | 2013-05-30 |
| NZ551455A (en) | 2012-03-30 |
| KR20070036067A (ko) | 2007-04-02 |
| CA2566741C (fr) | 2014-06-10 |
| EP1750718A4 (fr) | 2010-12-08 |
| RU2006140794A (ru) | 2008-06-27 |
| US8952017B2 (en) | 2015-02-10 |
| CA2566741A1 (fr) | 2005-12-01 |
| US20130281471A1 (en) | 2013-10-24 |
| AU2005244985A1 (en) | 2005-12-01 |
| AU2005244985B2 (en) | 2011-09-01 |
| US20080132527A1 (en) | 2008-06-05 |
| HK1097751A1 (en) | 2007-08-24 |
| MXPA06013295A (es) | 2007-02-22 |
| NO20065791L (no) | 2007-01-30 |
| CN1968699B (zh) | 2010-12-15 |
| EP1750718A1 (fr) | 2007-02-14 |
| RU2406504C2 (ru) | 2010-12-20 |
| JP5122954B2 (ja) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8952017B2 (en) | Acyclovir formulations | |
| KR100412298B1 (ko) | 콜로이드이산화규소를함유하는발라시클로비르정제 | |
| US20090124639A1 (en) | valacyclovir formulations | |
| JP6612200B2 (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
| US20120238591A1 (en) | Acyclovir formulations | |
| ES2339213T3 (es) | Clorhidrato de lercanidipino amorfo | |
| KR20210136081A (ko) | 화합물의 제제 및 그의 용도 | |
| AU2014277506A1 (en) | Bisulfate of Janus kinase (JAK) inhibitor and preparation method therefor | |
| JP2023516628A (ja) | ヌクレオチド系化合物のコロナウイルス感染症の治療での使用 | |
| RU2367442C2 (ru) | Способ нормализации мочеиспускания при нарушении функции почек | |
| JP2000503310A (ja) | １日１回の投与による陰部ヘルペス治療用医薬の製造のためのバラシクロビールの使用 | |
| SK280537B6 (sk) | Použitie derivátov xantínu na výrobu liečiv na oše | |
| JP2513519B2 (ja) | 薬剤組成物 | |
| WO2021047525A1 (fr) | Sel d'un composé de benzothiopyrone, son procédé de préparation et son utilisation | |
| WO2015016789A1 (fr) | Formulation en poudre de valganciclovir | |
| CN115089582B (zh) | 阿昔替尼在制备抑制肠道病毒71型嗜神经性病毒药物中的应用 | |
| RU2255086C1 (ru) | 1-метил-2-фенилтиометил-3-карбэтокси-4-диметиламинометил-5-окси-6- броминдола мезилат, обладающий противовирусной активностью, и фармацевтическая композиция с его использованием | |
| EP0082667A1 (fr) | Compositions pharmaceutiques | |
| JPH06227982A (ja) | 抗ウイルス剤 |